FDA calendar
Upcoming FDA decision dates, advisory committee meetings and EU opinions, alongside recent FDA decisions and announcements. Updated automatically every day from the FDA newsroom, openFDA, the Federal Register and company announcements.
Coming up
No upcoming events yet.
Recent FDA decisions and announcements
November 2026
- 9Mon
- 9MonFDA approvalFDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High RiskFDA press release β
- 5ThuFDA approvalFDA Grants Accelerated Approval to a New Treatment for Head and Neck Squamous Cell CarcinomaFDA press release β
October 2026
- 30FriFDA approvalFDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory PapillomatosisFDA press release β
- 30FriFDA approvalFDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory PapillomatosisFDA press release β
- 27Tue
- 22Thu
- 22Thu
- 22Thu
- 20TueFDA approvalGlaxosmithkline LLC Β· Hibsago (bepirovirsen)New molecular entity, priority reviewDrugs@FDA β
- 20Tue
- 20Tue
- 19MonFDA approvalFDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and SurgeryFDA press release β
- 19MonFDA approvalFDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and SurgeryFDA press release β
- 14WedFDA approvalFDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder CancerFDA press release β
- 9FriFDA approvalAicuris Anti-Infect Β· Hovilpri (pritelivir mesylate)New molecular entity, priority reviewDrugs@FDA β
September 2026
- 28Mon
- 28Mon
- 25FriFDA approvalMirum Β· Atebrioz (zilurgisertib fumarate)New molecular entity, priority reviewDrugs@FDA β
- 23WedFDA approvalElevar Β· Lyrfigtu (lirafugratinib hydrochloride)New molecular entity, priority reviewDrugs@FDA β
- 17ThuFDA approvalFDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type AFDA press release β
August 2026
- 26WedFDA approvalRevolution Medicines Β· Rasonque (daraxonrasib)New molecular entity, priority reviewDrugs@FDA β
- 13ThuFDA approvalBristol Myers Squibb Β· Zenbexus (iberdomide hydrochloride)New molecular entity, priority reviewDrugs@FDA β
- 13Thu
- 5WedFDA approvalTakeda Pharms USA Β· Orzeyful (oveporexton)New molecular entity, priority reviewDrugs@FDA β
July 2026
- 31Fri
- 24FriFDA approvalOutlook Therapeutics, Inc. Β· Lytenava (bevacizumab-vikg)New biologic licenceDrugs@FDA β
